Portolan Capital Management LLC Lowers Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Portolan Capital Management LLC reduced its position in Anika Therapeutics, Inc. (NASDAQ:ANIK – Get Rating) by 11.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 207,900 shares of the biotechnology company’s stock after selling 26,703 shares during the period. Portolan Capital […]

Related Keywords

United States ,Kentucky ,America , ,Anika Therapeutics Inc ,Mutual Of America Capital Management ,Quadrant Capital Group ,Anika Therapeutics ,Nasdaq ,Exchange Commission ,Tower Research Capital ,Barrington Research ,Portolan Capital Management ,Get Rating ,Capital Management ,Capital Group ,Research Capital ,America Capital Management ,Retirement System ,Visit Holdingschannel ,Anika Therapeutics Daily ,Nasdaq Anik ,Anik ,Medical ,03525510 ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,